Emerging systemic therapies for atopic dermatitis: biologics

References

• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090–1091.
   PubMedGoogle Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab. J Mol Biol. 2013;425(8):1330–1339.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871.e11.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Jr Hanania NA, et al. Lebrikizumab treatment in adults with asthma. New Eng J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411–420.
   PubMed Web of Science ®Google Scholar
• May R, Monk P, Cohen E, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. British J Pharmacol. 2012;166(1):177–193.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J All Clin Immunol. 2019;143(1):135–141.
   PubMed Web of Science ®Google Scholar
• Oyama S, Kitamura H, Kuramochi T, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018;27(1):14–21.
   PubMed Web of Science ®Google Scholar
• Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. British J Dermatol. 2016;174(2):296–304.
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J All Clin Immunol. 2006;117(2):411–417.
   PubMed Web of Science ®Google Scholar
• Kato A, Fujii E, Watanabe T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci. 2014;74(3):229–235.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti–interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J All Clin Immunol. 2018;142(4):1121–1130.e7.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J All Clin Immunol. 2020;145(1):173–182.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Shemer A, et al. despite reduced IL-17-producing TH17 T cells “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced. J All Clin Immunol. 2009;123(6):1244–1252.
   PubMed Web of Science ®Google Scholar
• Lou H, Lu J, Choi EB, et al. Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway. J Immunol. 2017;198(7):2543–2555.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872–881.e6.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nature Immunol. 2002;3(7):673–680.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013–1021.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J All Clin Immunol. 2019;144(2):482–493.e7.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67(9):1111–1117.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Spuls PI, Thomas KS, HOME initiative orators, et al. The harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J All Clin Immunol. 2014;134(4):800–807.
   PubMed Web of Science ®Google Scholar